Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Me, Rodríguez Ruiz"'
Publikováno v:
Europe PubMed Central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::92649e3f4e583e4c9799e1c757f74315
http://europepmc.org/abstract/med/26786375
http://europepmc.org/abstract/med/26786375
Autor:
Steeghs N; Netherlands Cancer Institute, Amsterdam, the Netherlands., Gomez-Roca C; Institut Universitaire du Cancer, Toulouse, France., Rohrberg KS; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark., Mau-Sørensen M; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark., Robbrecht D; Erasmus University Medical Center, Rotterdam, the Netherlands., Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), CIBERONC, Barcelona, Spain., Ahmed S; University Hospitals of Leicester NHS Trust, Leicester, United Kingdom., Rodríguez-Ruiz ME; Clinica Universidad de Navarra, CIBERONC, Pamplona, Spain., Ardeshir C; Roche Products Ltd., Welwyn Garden City, United Kingdom., Schmid D; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center, Munich, Germany., Sleiman N; Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland., Watson C; A4P Consulting Ltd., Sandwich, United Kingdom., Piper-Lepoutre H; Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland., Dejardin D; Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland., Evers S; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center, Basel, Switzerland., Boetsch C; Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland., Charo J; Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland., Teichgräber V; Netherlands Cancer Institute, Amsterdam, the Netherlands.; Institut Universitaire du Cancer, Toulouse, France., Melero I; Clinica Universidad de Navarra, CIBERONC, Pamplona, Spain.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 01; Vol. 30 (13), pp. 2693-2701.
Autor:
Garate-Soraluze E; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain., Marco-Sanz J; Program of Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain; Department of Pediatrics, University of Navarra Clinic, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Serrano-Mendioroz I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain., Marrodán L; Program of Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Fernandez-Rubio L; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain., Labiano S; Program of Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain; Department of Pediatrics, University of Navarra Clinic, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Rodríguez-Ruiz ME; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of Radiation Oncology, University of Navarra Clinic, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Electronic address: mrruiz@unav.es.
Publikováno v:
Methods in cell biology [Methods Cell Biol] 2024; Vol. 185, pp. 99-113. Date of Electronic Publication: 2024 Mar 23.
Autor:
Suárez L; Department of Biochemistry and Genetics, University of Navarra, 31008 Pamplona, Spain., Rodríguez-Ruiz ME; Division of Immunology and Immunotherapy, Center for Applied Medical Research, Universidad de Navarra, 31008 Pamplona, Spain.; Department of Radiation Oncology, University Clinic of Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Rouzaut A; Department of Biochemistry and Genetics, University of Navarra, 31008 Pamplona, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research, Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
Publikováno v:
Cancers [Cancers (Basel)] 2022 Dec 20; Vol. 15 (1). Date of Electronic Publication: 2022 Dec 20.
Autor:
Ruiz-Fernández de Córdoba B; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Moreno H; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Valencia K; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Perurena N; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Ruedas P; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Walle T; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Pezonaga-Torres A; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Hinojosa J; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Guruceaga E; Bioinformatics Core Facility, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Pineda-Lucena A; Program of Molecular Therapies, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Abengózar-Muela M; Departament of Pathology, Clínica University of Navarra, Pamplona, Spain., Cochonneau D; Nantes Université, CNRS, US2B, UMR 6286, Nantes, France.; Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine, Saint Herblain, France., Zandueta C; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Martínez-Canarias S; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain., Teijeira Á; Immunology and Immunotherapy, CIMA, Pamplona, Spain., Ajona D; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain., Ortiz-Espinosa S; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain., Morales X; Image Core Facility, CIMA, Pamplona, Spain., Ortiz de Solórzano C; Image Core Facility, CIMA, Pamplona, Spain., Santisteban M; Oncology, Clínica University of Navarra, Pamplona, Spain., Ramos-García LI; Radiation Oncology, Clínica University of Navarra, Pamplona, Spain., Guembe L; Morphology Core Facility, CIMA, Pamplona, Spain., Strnad V; Department of Radiation Oncology, University of Erlangen, Erlangen, Germany., Heymann D; Nantes Université, CNRS, US2B, UMR 6286, Nantes, France.; Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine, Saint Herblain, France.; Department of Oncology and Metabolism, Medical School, Sheffield, UK., Hervás-Stubbs S; Immunology and Immunotherapy, CIMA, Pamplona, Spain., Pío R; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain., Rodríguez-Ruiz ME; Immunology and Immunotherapy, CIMA, Pamplona, Spain.; Radiation Oncology, Clínica University of Navarra, Pamplona, Spain., de Andrea CE; Departament of Pathology, Clínica University of Navarra, Pamplona, Spain., Vicent S; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; School of Medicine, Department of Pathology, Anatomy and Physiology, University of Navarra, Pamplona, Spain., Melero I; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; Oncology, Clínica University of Navarra, Pamplona, Spain.; School of Medicine, Department of Pathology, Anatomy and Physiology, University of Navarra, Pamplona, Spain., Lecanda F; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; School of Medicine, Department of Pathology, Anatomy and Physiology, University of Navarra, Pamplona, Spain., Martínez-Monge R; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Oncology, Clínica University of Navarra, Pamplona, Spain.; Radiation Oncology, Clínica University of Navarra, Pamplona, Spain.
Publikováno v:
Cancer discovery [Cancer Discov] 2022 May 02; Vol. 12 (5), pp. 1356-1377.
Autor:
Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Garasa S; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Ochoa MDC; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Glez-Vaz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Andueza MP; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain., Migueliz I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Alvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Rodríguez-Ruiz ME; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain., Rouzaut A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Sanmamed MF; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain., Perez Gracia JL; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain.
Publikováno v:
European journal of immunology [Eur J Immunol] 2021 Sep; Vol. 51 (9), pp. 2274-2280. Date of Electronic Publication: 2021 Jun 04.
Autor:
Leaman Alcibar O; Radiation Oncology Department, Central University Hospital of Defence Gómez Ulla, Madrid, Spain. olwenleaman@gmail.com., Candini D; Radiation Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain., López-Campos F; Radiation Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain., Albert Antequera M; Radiation Oncology Department, La Ribera University Hospital, Valencia, Spain., Morillo Macías V; Radiation Oncology Department, General Hospital in Castellón de la Plana, Castellón, Spain., Conde AJ; Radiation Oncology Department, The University and Polytechnic La Fe Hospital, Valencia, Spain., Rodríguez Pérez A; Radiation Oncology Department, Internacional Ruber Hospital, Madrid, Spain., Hervás Morón A; Radiation Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain., Contreras Martínez J; Radiation Oncology Department, Málaga Hospital, Málaga, Spain., Ferrer Albiach C; Radiation Oncology Department, General Hospital in Castellón de la Plana, Castellón, Spain., Navarro Aguilar S; Radiation Oncology Department, Oncology and Radiotherapy Institut, Ricardo Palma Clinic, Lima, Peru., Rodríguez-Ruiz ME; Radiation Oncology Department, University of Navarra Clinic and CIMA, Navarra, Spain.
Publikováno v:
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2019 Aug; Vol. 21 (8), pp. 992-1004. Date of Electronic Publication: 2019 Jan 14.
Autor:
Rodríguez-Ruiz ME; Department of Oncology, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain. imelero@unav.es mrruiz@unav.es.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Rodríguez I; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Cellular Therapy, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Mayorga L; Department of Oncology, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Labiano T; Department of Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain., Barbes B; Department of Oncology, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Etxeberria I; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Ponz-Sarvise M; Department of Oncology, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Azpilikueta A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Bolaños E; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Sanmamed MF; Department of Oncology, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Berraondo P; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Calvo FA; Department of Oncology, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Barcelos-Hoff MH; Department of Radiation Oncology, University of California, San Francisco, San Francisco, California., Perez-Gracia JL; Department of Oncology, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Melero I; Department of Oncology, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain. imelero@unav.es mrruiz@unav.es.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2019 Mar; Vol. 18 (3), pp. 621-631. Date of Electronic Publication: 2019 Jan 25.
Autor:
Berraondo P; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain. pberraondol@unav.es.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain. pberraondol@unav.es.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain. pberraondol@unav.es., Sanmamed MF; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.; Department of Oncology and immunology, Clínica Universidad de Navarra, Pamplona, Spain., Ochoa MC; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain., Etxeberria I; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain., Aznar MA; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain., Pérez-Gracia JL; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.; Department of Oncology and immunology, Clínica Universidad de Navarra, Pamplona, Spain., Rodríguez-Ruiz ME; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.; Department of Oncology and immunology, Clínica Universidad de Navarra, Pamplona, Spain., Ponz-Sarvise M; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.; Department of Oncology and immunology, Clínica Universidad de Navarra, Pamplona, Spain., Castañón E; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.; Department of Oncology and immunology, Clínica Universidad de Navarra, Pamplona, Spain., Melero I; Immunology and Immunotherapy Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain. imelero@unav.es.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain. imelero@unav.es.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain. imelero@unav.es.; Department of Oncology and immunology, Clínica Universidad de Navarra, Pamplona, Spain. imelero@unav.es.
Publikováno v:
British journal of cancer [Br J Cancer] 2019 Jan; Vol. 120 (1), pp. 6-15. Date of Electronic Publication: 2018 Nov 09.
Autor:
Sánchez-Paulete AR; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Teijeira Á; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Quetglas JI; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Rodríguez-Ruiz ME; University Clinic, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Sánchez-Arráez Á; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Labiano S; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Etxeberria I; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Azpilikueta A; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Bolaños E; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain.; CIBERONC, Instituto de Investigación Carlos III, Madrid, Spain., Ballesteros-Briones MC; Division of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Casares N; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Quezada SA; Cancer Immunology Unit, University College London Cancer Institute, University College London, London, United Kingdom., Berraondo P; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain.; CIBERONC, Instituto de Investigación Carlos III, Madrid, Spain., Sancho D; Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain., Smerdou C; Division of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain., Melero I; Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain. imelero@unav.es.; University Clinic, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain.; CIBERONC, Instituto de Investigación Carlos III, Madrid, Spain.
Publikováno v:
Cancer research [Cancer Res] 2018 Dec 01; Vol. 78 (23), pp. 6643-6654. Date of Electronic Publication: 2018 Oct 08.